Merit Medical Acquires DFINE, Inc.

SOUTH JORDAN, Utah, July 06, 2016 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading manufacturer and marketer of proprietary disposable devices used primarily in cardiology, radiology and endoscopy, today announced that it has acquired DFINE, Inc. headquartered in San Jose, California, in a merger transaction through which DFINE has become a wholly-owned subsidiary…

Commercial Launch of the Long SpineSTAR® Ablation Instrument

DFINE® Announces Commercial Launch of the Long SpineSTAR® Ablation Instrument for the Palliative Treatment of Metastatic Spine Tumors SpineSTAR’s extended working length provides spine specialists greater access and ability to precisely target metastatic spine tumors in order to offer patients rapid, sustained pain relief improving their quality of life.  San Jose, Calif. (PRWEB) December 15,…

First Patients Enrolled in the STARRT Clinical Study

San Jose, Calif. January 23, 2015 — DFINE, Inc.,announced today that the first two patients have been enrolled in the STARRT Clinical Trial at Providence Sacred Heart Medical Center, Spokane WA. The multi-center trial is the first prospective study to evaluate the treatment of painful metastatic lesions with STAR Targeted Radiofrequency Ablation (t-RFA) and Radiofrequency Targeted Vertebral Augmentation (RF-TVA) prior to or following radiation therapy.

Multi-Center Trial Shows Significant Pain Relief For Spine Cancer Patients Following Targeted Radiofrequency Ablation Treatment

SAN JOSE, Calif. – July 21, 2014 – DFINE®, Inc., a market leader in the minimally invasive treatment of spinal diseases, today announced the publication of a multi-center study in the July/August issue of Pain Physician Journal, the official peer-reviewed publication of the American Society of Interventional Pain Physicians (ASIPP). The study followed patients at…

DFINE Announces Commencement Of Clinical Study On Spinal Tumor Ablation With The STAR Tumor Ablation System

San Jose, Calif. and Magdeburg, Germany – June 11, 2014 – DFINE®, Inc., a market leader in the minimally invasive treatment of spinal diseases, today announced that the first patient has been enrolled in the EU-STAR Clinical Trial. The multi-center trial is the first prospective study to evaluate clinical outcomes in patients receiving treatment with…

New Studies Highlight Benefits Of STAR Tumor Ablation System For Patients With Spinal Tumors

San Jose, Calif. – Feb. 18, 2014 –Two studies presented at the American Society of Spine Radiology (ASSR) 2014 Annual Symposium in Miami highlighted the benefits of Targeted Radiofrequency Ablation™ (t-RFA) therapy with the DFINE STAR™ Tumor Ablation System. The studies demonstrated the ability of the STAR System to provide significant pain relief to patients…